News: Grants and Funding

Elixirgen Therapeutics, Inc. raises $5 million in Series B round

BALTIMORE, November 19, 2019 – Elixirgen Therapeutics, Inc. has raised $5 million in Series B funds from current investors in the company.

With these funds, Elixirgen Therapeutics will continue development of its lead candidate, EXG34217, a therapy that uses the ZSCAN4 gene to treat people with Telomere Biology Disorders with Bone Marrow Failure, as well as other therapy pipelines.